Given the association of Hs-BUB1 and Hs-BUBR1 in oncogenesis and aneuploidy (Kops et al., 2005) and the oncogenic property of the fusion of Hs-Blinkin (AF15q14) with the MLL gene in acute myeloid leukemia and lung cancer (Hayette et al., 2000), it would be worthwhile to explore further whether the N-terminal region of Hs-BUB1 (and also that of Hs-BUBR1) constitutes a suitable target for drug discovery. This evidence concerns the gene KMT2A and acute myeloid leukemia.